Phare Bio

Phare Bio is a non-profit biotech social venture dedicated to developing a pipeline of novel antibiotics to combat the global threat of antimicrobial resistance (AMR). Launched by the Wyss Institute at Harvard and the Collins Lab at MIT, the company utilizes advanced artificial intelligence and deep learning platforms to identify and develop new classes of antibiotics. Its lead program, Halicin, is a small molecule discovered through AI that demonstrates potent activity against a broad spectrum of drug-resistant pathogens. Phare Bio operates with a mission-driven model to ensure that life-saving treatments reach patients regardless of commercial profitability.